Skip to main content
Company profile
Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

Pipeline11 assets

  • B-VECB-VEC / VYJUVEK / Type VII collagen (COL7A1) / Gene Therapy (HSV-1 vector) / Dermatology
    Dystrophic Epidermolysis Bullosa (DEB)CommercialApprovedGlobal
  • KB105KB105 / Transglutaminase 1 (TGM1) / Gene Therapy / Dermatology
    TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)Phase 1/2ActiveGlobal
  • KB104KB104 / Serine Peptidase Inhibitor Kazal Type 5 (SPINK5) / Gene Therapy / Dermatology
    Netherton SyndromePreclinicalActiveGlobal
  • KB407KB407 / Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) / Gene Therapy / Respiratory
    Cystic FibrosisPhase 1ActiveGlobal
  • KB408KB408 / Alpha-1 antitrypsin / Gene Therapy / Respiratory
    Alpha-1 Antitrypsin Deficiency (AATD)PreclinicalActiveGlobal
  • KB707KB707 / IL-12 and IL-2 / Gene Therapy (HSV-1 vector) / Oncology
    Locally advanced or metastatic solid tumor malignanciesPhase 1ActiveGlobal
  • KB301KB301 / Type III collagen / Gene Therapy / Aesthetics
    Aesthetic Skin ConditionsPhase 1/2ActiveGlobal
  • KB302KB302 / Type I collagen / Gene Therapy / Aesthetics
    Aesthetic Skin ConditionsPreclinicalActiveGlobal
  • KB303KB303 / Elastin / Gene Therapy / Aesthetics
    Aesthetic Skin ConditionsPreclinicalActiveGlobal
  • KB304KB304 / Type III collagen and Elastin / Gene Therapy / Aesthetics
    Aesthetic Skin ConditionsPreclinicalActiveGlobal
  • KB305KB305 / Type IV collagen / Gene Therapy / Aesthetics
    Aesthetic Skin ConditionsPreclinicalActiveGlobal

Latest news4 items

All news

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will take part in a fireside chat scheduled at 3:55 pm

Krystal Biotech, Inc. • Endpoint Arena